Diabetes mellitus (main): Difference between revisions

Line 32: Line 32:
*[[EBQ:Sodium_Bicarbonate_use_in_DKA|Evidence Review Sodium Bicarbonate in DKA]]
*[[EBQ:Sodium_Bicarbonate_use_in_DKA|Evidence Review Sodium Bicarbonate in DKA]]
*[[EBQ:Relevance of Discharge Glucose Levels]]
*[[EBQ:Relevance of Discharge Glucose Levels]]


Revision as of 04:05, 10 November 2018


  • Growing in worldwide prevalence
  • Results from either inability of the body to release insulin from the pancreas or a resistance against the actions of insulin

Clinical Features

  • Patients with diabetes may be asymptomatic
  • Acute symptoms range from those of nonketotic hyperglycemia (e.g. polyuria, polydipsia) to DKA (ill appearance, acetone breath, Kussmaul's breathing, somnolence)

Differential Diagnosis



  • Diabetes mellitus itself is not normally a diagnosis sought in the emergency department (i.e. via A1C)
  • Hyperglycemia can be found on laboratory testing
    • Asymptomatic patients do not necessarily require additional testing
    • Symptomatic or potentially symptomatic patients require additional testing
      • Check CBC, BMP, and ketones (if sick, additionally see DKA workup)
      • UA is only necessary if you are ruling out urinary infection or do not have serum ketones available and are using it as a screening mechanism


Type II Diabetes Outpatient Management

  • 1st line: Metformin 500mg BID → 1000mg BID, do not give in people with abnormal LFT's, CHF Stage 3/4 and ARI, CKD
  • 2nd Agent: Glipizide start 2.5mg BID → 5mg BID, need to monitor for hypoglycemia
  • 3rd Agent: Pioglitazone
  • After 3 agents: need to start insulin if not controlled
    • NPH BID or Lantus Qday (0.1 to 0.2mg/kg) and titrate to Fasting Blood Sugar


See Also